One phlebotomist can supervise three machines. The needle detaches automatically if the patient moves. Success rates were comparable to or better than trained humans.
The second company this year to bet on post-bariatric hypoglycaemia — and it is taking a completely different mechanistic route to the same problem.
Gamma-delta T cells do not check MHC before killing. That single property is what makes an off-the-shelf cell therapy chemically possible.
A vaccine built individually for each patient from their own tumour’s mutations. The first randomised Phase 3 to test whether that works — and it did.
The transplanted cells did not replace what was lost. They relayed around it — which is why a neck injury that stops breathing might be bypassed rather than repaired.
Engineered human bone and lung tissue connected by a circulating blood channel. Breast cancer cells introduced into the flow colonised the organs the way they do in patients — and prepared them first.
Lymph-node-like immune structures sit in the skull’s bone marrow, connected to the brain, and respond to glioblastoma before distant lymph nodes notice it. A gel under the scalp made them work harder.
Tau does not just tangle in the cell. It gets inside the mitochondria and makes the electron chain run backwards, generating the damage that makes more tau.
An 83.4% reduction in the risk of progression or death is an unusual number. Over 90% of patients progression-free at six months were still progression-free at three years.
More than 90% of pancreatic cancers are driven by KRAS, and KRAS was called undruggable for forty years. Median survival went from 6.7 months to 13.2.
Glioblastoma kills because surgeons cannot see every last cell. These nanoparticles make clusters half a hair’s width visible — then stay behind to destroy what the scalpel missed.
The industry is building GLP-1 agonists. Amylyx bought a GLP-1 <em>blocker</em> out of a bankruptcy for $35 million — and it just cut severe hypoglycaemia by 55%.